Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
NEW YORK (
) has been downgraded by TheStreet Ratings from buy to hold. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and poor profit margins.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Highlights from the ratings report include:
- The revenue growth came in higher than the industry average of 3.8%. Since the same quarter one year prior, revenues rose by 20.1%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
- The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 609.3% when compared to the same quarter one year prior, rising from $0.53 million to $3.74 million.
- Compared to where it was a year ago today, the stock is now trading at a higher level, reflecting both the market's overall trend during that period and the fact that the company's earnings growth has been robust. Looking ahead, the stock's rise over the last year has already helped drive it to a level which is relatively expensive compared to the rest of its industry, implying reduced upside potential.
- The gross profit margin for SYMMETRY MEDICAL INC is currently lower than what is desirable, coming in at 28.00%. Regardless of SMA's low profit margin, it has managed to increase from the same period last year. Despite the mixed results of the gross profit margin, SMA's net profit margin of 3.70% is significantly lower than the same period one year prior.
- The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, SYMMETRY MEDICAL INC's return on equity significantly trails that of both the industry average and the S&P 500.
Symmetry Medical Inc. and its subsidiaries designs, develops, and produces implants and related surgical instruments, and cases primarily to orthopedic device manufacturers worldwide. The company has a P/E ratio of 105.4, above the S&P 500 P/E ratio of 17.7. Symmetry Medical has a market cap of $310.1 million and is part of the health care sector and health services industry. Shares are up 7.3% year to date as of the close of trading on Monday.
You can view the full
or get investment ideas from our
-- Written by a member of TheStreet Ratings Staff
FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!